Dacomitinib (CAS 1110813-31-4)

Application and positioning

Dacomitinib is an irreversible pan-HER tyrosine kinase inhibitor targeting EGFR, HER2 and HER4. It is used in oral tablets for first-line treatment of EGFR-mutant non-small cell lung cancer. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.

Quality and documentation

• Batch-specific Certificate of Analysis issued by the manufacturing site
• SDS/MSDS and specification sheet available on request
• Residual solvents and elemental impurities statements discussed per project
• For pharmaceutical manufacturing and R&D use only — not for direct administration

Packaging and handling

• Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
• Small quantities in sealed aluminium foil bags
• Palletised for air and sea freight; store dry, ventilated and protected from light

Related products

• Ibrutinib (CAS 936563-96-1)
• Larotrectinib Sulfate (CAS 1223405-08-0)
• Lenvatinib Mesylate (CAS 857890-39-2)
• Lorlatinib (CAS 1454846-35-5)
• N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitro-4-quinazolinamine (CAS 162012-67-1)
• N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine (CAS 179552-74-0)

Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.